228 related articles for article (PubMed ID: 23737728)
1. RNA editing and drug discovery for cancer therapy.
Huang WH; Tseng CN; Tang JY; Yang CH; Liang SS; Chang HW
ScientificWorldJournal; 2013; 2013():804505. PubMed ID: 23737728
[TBL] [Abstract][Full Text] [Related]
2. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
Ganem NS; Ben-Asher N; Lamm AT
Drug Resist Updat; 2017 May; 32():16-22. PubMed ID: 29145975
[TBL] [Abstract][Full Text] [Related]
3. RNA editing affects cis-regulatory elements and predicts adverse cancer survival.
Wu YM; Guo Y; Yu H; Guo T
Cancer Med; 2021 Sep; 10(17):6114-6127. PubMed ID: 34319007
[TBL] [Abstract][Full Text] [Related]
4. Clinical Applications of RNA Editing Technology for the Early Detection of Cancer and Future Directions.
Ullah M; Akbar A; Yannarelli G
Technol Cancer Res Treat; 2020; 19():1533033820964194. PubMed ID: 33124527
[TBL] [Abstract][Full Text] [Related]
5. GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers.
Ruan H; Li Q; Liu Y; Liu Y; Lussier C; Diao L; Han L
Nucleic Acids Res; 2022 Jan; 50(D1):D1231-D1237. PubMed ID: 34534336
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of RNA and DNA editing in cancer.
Avesson L; Barry G
Biochim Biophys Acta; 2014 Apr; 1845(2):308-16. PubMed ID: 24607277
[TBL] [Abstract][Full Text] [Related]
7. Artificial RNA Editing with ADAR for Gene Therapy.
Bhakta S; Tsukahara T
Curr Gene Ther; 2020; 20(1):44-54. PubMed ID: 32416688
[TBL] [Abstract][Full Text] [Related]
8. The Development of TALE Nucleases for Biotechnology.
Ousterout DG; Gersbach CA
Methods Mol Biol; 2016; 1338():27-42. PubMed ID: 26443211
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer.
Hong H; An O; Chan THM; Ng VHE; Kwok HS; Lin JS; Qi L; Han J; Tay DJT; Tang SJ; Yang H; Song Y; Bellido Molias F; Tenen DG; Chen L
Nucleic Acids Res; 2018 Sep; 46(15):7953-7969. PubMed ID: 29796672
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
Chen HX
Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768
[No Abstract] [Full Text] [Related]
11. miRNA Editing: New Insights into the Fast Control of Gene Expression in Health and Disease.
Mingardi J; Musazzi L; De Petro G; Barbon A
Mol Neurobiol; 2018 Oct; 55(10):7717-7727. PubMed ID: 29460265
[TBL] [Abstract][Full Text] [Related]
12. Chromatin engineering offers an opportunity to advance epigenetic cancer therapy.
Baskin NL; Haynes KA
Nat Struct Mol Biol; 2019 Oct; 26(10):842-845. PubMed ID: 31582843
[No Abstract] [Full Text] [Related]
13. Putative impact of RNA editing on drug discovery.
Decher N; Netter MF; Streit AK
Chem Biol Drug Des; 2013 Jan; 81(1):13-21. PubMed ID: 23253127
[TBL] [Abstract][Full Text] [Related]
14. Does RNA editing play a role in the development of urinary bladder cancer?
Zilberman DE; Safran M; Paz N; Amariglio N; Simon A; Fridman E; Kleinmann N; Ramon J; Rechavi G
Urol Oncol; 2011; 29(1):21-6. PubMed ID: 19186082
[TBL] [Abstract][Full Text] [Related]
15. RNA editors: key regulators of viral response in cancer patients.
Priyadharsini JV; Paramasivam A
Epigenomics; 2021 Feb; 13(3):165-167. PubMed ID: 33499661
[No Abstract] [Full Text] [Related]
16. Splicing Regulators and Their Roles in Cancer Biology and Therapy.
da Silva MR; Moreira GA; Gonçalves da Silva RA; de Almeida Alves Barbosa É; Pais Siqueira R; Teixera RR; Almeida MR; Silva Júnior A; Fietto JL; Bressan GC
Biomed Res Int; 2015; 2015():150514. PubMed ID: 26273588
[TBL] [Abstract][Full Text] [Related]
17. Biological significance of RNA editing in cells.
Tang W; Fei Y; Page M
Mol Biotechnol; 2012 Sep; 52(1):91-100. PubMed ID: 22271460
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
Yang J; Meng X; Pan J; Jiang N; Zhou C; Wu Z; Gong Z
RNA Biol; 2018 Jan; 15(1):35-43. PubMed ID: 29028415
[TBL] [Abstract][Full Text] [Related]
19. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.
Chan TH; Lin CH; Qi L; Fei J; Li Y; Yong KJ; Liu M; Song Y; Chow RK; Ng VH; Yuan YF; Tenen DG; Guan XY; Chen L
Gut; 2014 May; 63(5):832-43. PubMed ID: 23766440
[TBL] [Abstract][Full Text] [Related]
20. ADAR1: A New Target for Immuno-oncology Therapy.
Bhate A; Sun T; Li JB
Mol Cell; 2019 Mar; 73(5):866-868. PubMed ID: 30849393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
